Eli Lilly: promising results in Crohn's disease

(CercleFinance.com) - Eli Lilly announces the results of the 'VIVID-2' open-label extension study, which showed that the majority of patients with moderate-to-severe Crohn's disease who received two years' continuous treatment with Omvoh (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including 43.
8% who had failed prior biologic therapy.

This treatment targets the interleukin-23p19 protein, key in intestinal inflammation.

Among the results obtained after two years of treatment, 92.9% of patients in clinical remission at one year remained in remission, and 87.6% maintained an endoscopic response, with 78.6% remaining in endoscopic remission.


Copyright (c) 2025 CercleFinance.com. All rights reserved.